Alnylam and Sanofi commence Phase III programme for haemophilia drug

Alnylam Pharmaceuticals and Sanofi Genzyme have commenced the Phase III clinical programme (ATLAS) of RNAi therapeutic fitusiran in patients with haemophilia A or B, with or without inhibitors.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news